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Dendritic cells (DCs) and their subsets have multi-
faceted roles in the early stages of HIV-1 transmission
and infection. DC studies have led to remarkable
discoveries, including identification of restriction fac-
tors, cellular structures promoting viral transmission
including the infectious synapse or the interplay of the
C-type lectins, Langerin on Langerhans cells (LCs), and
dendritic cell-specific intercellular adhesion molecule-
3-grabbing non-integrin on other DC subsets, limiting
or facilitating HIV transmission to CD4þ T cells,
respectively. LCs/DCs are also exposed to encounter-
ing HIV-1 and other sexually transmitted infections
(herpes simplex virus-2, bacteria, fungi), which repro-
gram HIV-1 interaction with these cells. This review will
summarize advances in the role of DCs during HIV-1
infection and discuss their potential involvement in
the development of preventive strategies against HIV-1
and other sexually transmitted infections.
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INTRODUCTION
At the start of this century, the Millennium Development Goal
6 called for global efforts to halt and begin to reverse the AIDS
epidemic. The UN Political Declaration on HIV/AIDS has
supported this and set forth a series of ambitious targets and
elimination commitments for 2015. Globally, an estimated
35.3 million people were living with HIV in 2012 (http://
www.unaids.org), an increase from previous years as more
people are now receiving life-saving anti-retroviral treatment,
but significant challenges remain in the fight against HIV.
HIV-1 is transmitted through sexual intercourse by crossing
epithelial barriers at mucosal surfaces of the genital and
anorectal tracts (reviewed in Harman et al. (2013b)).
Since their discovery 40 years ago (Steinman and Cohn,
1973), dendritic cells (DCs) and their subsets have been
shown to have a major role in immune defence against viral
infection by generating and regulating innate and adaptive
immune responses. Because of their strategic location at mucosal
surfaces, effectiveness at antigen capture, potent migratory
ability, and their privileged interaction with effector T cells in
lymphoid tissues, DCs are likely critical intermediates of HIV
infection and transmission (reviewed in Piguet and Steinman
(2007); Haase (2010); Steinman (2012)).
In this review, we will summarize the evidence supporting
the importance of DC biology in HIV disease and highlight
some of the developments that may have important implica-
tions in both prevention and treatment of HIV/AIDS.
BIOLOGY OF DCs AND THEIR SUBSETS
Human skin and mucosal tissues are populated by immature
DCs, which are characterized by their specific localization
and cell surface receptor expression. DCs capture and inter-
nalize, invading pathogens, and subsequently process antigen
on major histocompatibility complex class I and class II mole-
cules to CD8þ and CD4þ T cells, respectively (Steinman and
Banchereau, 2007). However, antigen presentation alone by
DCs is not enough to induce effective T-cell responses against
pathogens. CD4þT cells need to differentiate into distinct
T helper cell subsets depending on the type of infection into
T helper1, T helper2, T helper17, or regulatory T cells.
Pathogen recognition is critical to this induction of T-cell
differentiation. Despite there being a large variety of pathogens,
groups of pathogens share similar structures known as
pathogen-associated molecular patterns, which enable their
recognition (Akira et al., 2006). DCs express numerous pattern
recognition receptors that interact with pathogen-associated
molecular patterns inducing cytokine expression and the
C-type lectin receptors (CLRs) are a major class of pattern
recognition receptors. These CLRs bind pathogens, as well as
trigger signaling cascades. The unique position of DCs at the
interface with the environment is associated with their pivotal
role as sentinels of the immune system. Furthermore, by acting
as detectors of foreign danger signals, DCs bridge together the
innate and adaptive immune system. Upon pathogen encounter,
DCs undergo maturation. During maturation, DCs upregulate
molecules on their surface such as the major histocompa-
tibility complex class II, CD80, CD83, CD86, and CD40, which
are important for antigen presentation and T-cell stimulation.
DCs also migrate from the periphery to the secondary
lymphoid organs where they can induce CD8þ and CD4þ
T-cell responses (Banchereau and Steinman, 1998).
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In human skin, at least three DC subsets have been
identified: epidermal CD207þ Langerhans cells (LCs),
CD14þ dermal DCs, and CD14CD207CD1aþ DCs. LCs
specifically expressing the CLR CD207 (Langerin) (reviewed in
Romani et al. (2012); van den Berg and Geijtenbeek (2013))
are mainly found in the epidermal layer (Valladeau et al.,
1999, 2000), whereas subsets of dermal DCs, some expressing
CD209 dendritic cell–specific intercellular adhesion mole-
cule-3-grabbing non-integrin (DC-SIGN), are found through-
out the dermis (Lenz et al., 1993; Nestle et al., 1993; Pavli
et al., 1993). Langerin expressing cells have also been
observed in very low numbers in the human dermis and
may represent a subset of the CD1aþ dermal DC population
(Harman et al., 2013a) or epidermal LCs transitting through
the dermis. In peripheral blood, there are at least two major
subsets of DCs, which are both antigen presenting cells with
some functional differences: CD11cþ myeloid DCs, which
express either CD1c (blood dendritic cell antigen-1 (BDCA-1))
or CD141 (BDCA3), and CD11cCD123þ plasmacytoid DCs
(pDCs), which express BDCA-2, BDCA-4, and CD123
(interleukin-3 receptor (IL-3R)) and produce a large amount
of type I IFN in response to foreign antigen (reviewed in
Manches et al. (2012); Manches et al. (2014)).
In addition, with improvements to both flow cytometric and
genomic approaches, several other distinct subsets of DCs
have been recently identified. CLEC9Aþ /BDCA3þ DCs,
originally identified in peripheral blood and lymph nodes, have
recently been detected in the skin, liver, lung, and intestine.
They show a more mature phenotype compared with
CLEC9Aþ /BDCA3þ DCs observed in either blood or lymph
nodes, indicating that they may represent a mature stage of
differentiation (Chu et al., 2012; Haniffa et al., 2012).
HIV-1 BINDING AND CAPTURE
HIV-1 infection mostly occurs through vaginal or rectal routes,
as these submucosal areas are rich in DCs and their subsets.
HIV-1 infected DCs are difficult to detect compared with the
rapid and massive simian immunodeficiency virus (SIV)
infection detected in CD4þCCR5þ T cells (Brenchley et al.,
2004; Mehandru et al., 2004; Li et al., 2005; Mattapallil et al.,
2005). Nevertheless, it is likely that DCs, because of their
localization, act as early targets for the virus and subsequently
contribute to the spread of HIV-1 infection to CD4þ T cells via
infectious synapses (IS) (McDonald et al., 2003) and reviewed
by Wu and KewalRamani (2006); Piguet and Steinman (2007).
Viral uptake mainly occurs via endocytosis after binding to
CLRs (DC-SIGN, Langerin, CLEC4A (also known as DC
immunoreceptor; Altfeld et al., 2011). See Figure 1.
Apart from HIV-1 binding to DCs expressing the CLR DC-
SIGN (Geijtenbeek et al., 2000; Arrighi et al., 2004), other
specific DC subsets also express receptors that are able to bind
glycoprotein envelope gp120 (Turville et al., 2002; de Witte
et al., 2007a). In the subepithelia and lamina propria, DCs
bind HIV-1 via DC immunoreceptor (Lambert et al., 2008,
2011). However, gp120 binding and HIV recognition by pDCs
are mainly via CD4-mediated endocytosis, despite pDCs also
expressing CD4 and the CLR, BDCA-2 (Sandgren et al., 2013;
Manches et al., 2014).
HIV-1 capture involving interactions with glycosphingoli-
pids in the virus lipid bilayer have also been described on
immature or matured DCs (Gummuluru et al., 2003; Hatch
et al., 2009; Izquierdo-Useros et al., 2009).
HIV-1 capture in a glycosphingolipid-dependant manner
via the type I IFN-inducible Siglec-1 (CD169) has recently
been shown (Puryear et al., 2013). Selective downregulation
of CD169 expression or depletion of glycosphingolipids from
virions blocked DC-mediated HIV-1 viral capture and trans-
infection.
DC lectin receptors are also important molecules involved
in foreign antigen presentation (Engering et al., 2002). Most
HIV-1 virions captured by DCs are known to be at least in part
degraded (Turville et al., 2004; Garcia et al., 2005; Nobile
et al., 2005; Blanchet et al., 2010), but HIV-1 binding to
DC-SIGN does not lead to full degradation. Instead, some is
retained in intracellular compartments connected to the cell
surface, often termed virus containing compartment (Garcia
et al., 2008; Nikolic et al., 2011), which may facilitate
delivery to uninfected T cells via the IS. In macrophages, a
similar structure was described (Pelchen-Matthews et al.,
2003; Harris et al., 2011). In mature DCs, HIV-1 uptake and
infection leads to its co-localization within cholesterol-
enriched and tetraspanin-containing compartments, with
subsequent delivery of virus via an exosome-like pathway
(Izquierdo-Useros et al., 2009). However, in epidermal LCs,
virions are directed to acidic compartments for rapid viral
degradation (de Witte et al., 2007b) and in pDCs endocytosed
HIV-1 localizes to early endosomes triggering type I IFN
(O’Brien et al., 2011). This shows that the interplay between
HIV-1 and its binding receptors on DC subsets is quite com-
plex as opposing outcomes are seen between C-type lectins on
LCs and DCs. This may have implications on designing
microbicides, as disarming DC-SIGN on DCs could decrease
HIV-1 transmission, whereas disarming Langerin on LCs could
prove counterproductive. This could be one reason why
Mannan proved ineffective in a SIV model of mucosal
transmission, as it inhibited both DC-SIGN and Langerin
(Veazey et al., 2005). In contrast, inhibiting CCR5, viral
fusion, or both CD4/CCR5 seemed more promising in this
model.
TRANS AND CIS INFECTIONS OF DC SUBSETS BY HIV-1
Two phases of HIV-1 viral transfer from DCs to T cells have
been described (Turville et al., 2004; Wu and KewalRamani,
2006). First, trans-infection where the virus is at or near the
donor cell surface and transmitted to a different target cell via
the IS (McDonald et al., 2003; Arrighi et al., 2004; Nikolic
et al., 2011) or via the exosome secretion pathway (Cavrois
et al., 2007; Dong et al., 2007; Izquierdo-Useros et al., 2007).
This first phase is within 24 hours post HIV-1 exposure and
could involve trafficking of captured virus from the endo-
lysosomal pathway to the DC-T-cell synapse. In trans-
infection, HIV-1 can bind to DC-SIGN and be polarized to a
pocket structure connected to the cell surface. After DC-
CD4þT cell contact is established, the IS is formed and sta-
bilized through interactions between ICAM-1 and leukocyte
function–associated molecule-1 (Garcia et al., 2005;
Z Ahmed et al.
Role of DCs in HIV-1 Infection
1226 Journal of Investigative Dermatology (2015), Volume 135
Choudhuri et al., 2014). In immature DCs, HIV-1 leads to
Cdc42 activation and the formation of a protrusion at the DC
cell surface, which facilitates transfer of HIV-1 to CD4þ
T cells across the IS (Nikolic et al., 2011). In contrast, in lipo-
polysaccharide-matured DCs, via actin cytoskeleton rearran-
gements, the CD4þT cell then extends a filipodium into the
pocket on the DC surface to capture HIV-1 (Felts et al., 2010).
It is likely that rapid and efficient IS-mediated viral transfer
occurs between DCs and CD4þT cells in vitro, but the
importance of the IS is more difficult to establish in vivo.
However, recent data obtained in a humanized mouse model
of HIV infection strongly supports a key role for viral cell-
to-cell transmission (Murooka et al., 2012). Secondly,
cis-infection is where HIV-1 can infect target cells and
productively replicate, producing progeny virions. These
virions then subsequently infect new target cells. This
second phase is 24–72 hours after exposure and requires de
novo replication of virus in DCs.
Long-term HIV transmission mediated by DCs depends
on viral production by the DC. It has been observed that
immature DCs can retain intact virions for up to 6 days post
HIV-1 exposure (Trumpfheller et al., 2003). As most incoming
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Figure 1. Human dendritic cell (DC) subsets and the role in HIV infection. LCs, Langerhans cells; pDCs, plasmacytoid dendritic cells.
Z Ahmed et al.
Role of DCs in HIV-1 Infection
www.jidonline.org 1227
viruses are degraded in monocyte-derived dendritic cells within
24 hours (Moris et al., 2006), any virus transmitted from DCs
to T cells must be a newly synthesized progeny virus.
INTERACTIONS OF HIV WITH LCs
HIV-1 must penetrate the superficial layers of the epidermis to
gain access to LCs and resting T cells as potential target cells.
The role of LCs in initial HIV/SIV acquisition is supported by
in vivo and ex vivo studies. It has been observed that up to
90% of initially infected target cells were LCs in Rhesus
macaques exposed to intra-vaginal SIV (Hu et al., 2000).
Human foreskin explants in ex vivo experiments show that
epidermal LCs are targets for HIV-1 (Ganor et al., 2010; Zhou
et al., 2011). LCs may provide protected intracellular transport
of HIV to CD4þ T cells in the submucosal lymphoid tissue
and then to draining lymph nodes (Kawamura et al., 2000;
Cunningham et al., 2008). CD4, CCR5, and CLR expression
on LCs in endocervical mucosa and foreskin is thought to be a
basis for the preferential sexual transmission of R5 HIV-1. In
fact, epidermal LCs are preferentially infected by R5 HIV-1,
ex vivo, but not X4 HIV-1, and result in high infectivity levels
when cocultured with CD4þ T cells (Kawamura et al., 2000;
Ogawa et al., 2013). Monocyte-derived LCs are also readily
infected in vitro with R5 HIV-1 and treating this cultured
LCs with recombinant CD40L can further enhance HIV-1
replication (Kawamura et al., 2001). Although Langerin
impairs infection of LCs by HIV-1, there is a saturation of
Langerin at higher virus concentrations that overwhelms the
protective mechanism of action (de Witte et al., 2007b).
Recently, the neuropeptide, calcitonin gene–related peptide,
was shown to limit HIV-1 transfer from LCs to T cells through
multiple steps, such as increasing Langerin expression (Ganor
et al., 2013). It has been reported that vaginal LCs are able to
transfer HIV-1 to T cells independent of cis-infection (Hladik
et al., 2007; Ballweber et al., 2011). Contrary to this, topical
application of CCR5 inhibitors has been shown to completely
protect Rhesus macaques from intra-vaginal exposure to SHIV,
a chimeric simian/human immunodeficiency virus, whereas
the CLR-inhibitor, Mannan, could not (Lederman et al., 2004;
Veazey et al., 2005). Consistent with these findings, unlike
DCs, human LCs have been shown to acquire HIV-1 and
transmit the virus to T cells via cis-infection rather than trans-
infection (Kawamura et al., 2003; Peressin et al., 2014).
HIV RESTRICTION AND RECOGNITION
Despite DCs being a vehicle for trans-infection, they are
themselves poorly infected compared with T cells (Smed-
Sorensen et al., 2005).The restriction of X4 HIV-1, and to a
lesser degree of R5 HIV-1, replication in DCs could depend on
the differential expression of CD4 and chemokine receptors at
the cell surface, despite all the receptors being shown to be
functionally present (Popov et al., 2005; Pion et al., 2007), and
fusion of X4 HIV-1 with immature DCs was seemingly
restricted irrespective of surface levels of CXCR4 (Pion et al.,
2007). Currently, at least four cellular restriction factors have
been shown to block HIV-1 replication at different stages of
infection: apolipoprotein B mRNA-editing enzyme catalytic
polypeptide-like 3G or 3F (APOBEC3G/3F), tripartite motif-5a,
bone marrow stromal cell antigen-2 (tetherin/CD317), and
sterile alpha motif and HD domain 1 (SAMHD1; Laguette and
Benkirane, 2012) and reviewed in Kirchhoff (2010).
APOBEC3F/G are members of the cytidine deaminase
family that can significantly restrict HIV-1 replication in DCs
at a post-entry step (Pion et al., 2006; Mohanram et al., 2013).
It can be marked for degradation by the virion infectivity
factor via ubiquitination and degradation by the proteosome
pathway (Sheehy et al., 2003). It was recently shown that A3A
is the only member of the APOBEC3 family specifically
expressed in primary blood cells of myeloid origins and
expression levels increase during HIV-1 spread in infected
macrophages (Berger et al., 2011). See Figure 2.
Tripartite motif-5a, important for interspecies retroviral
replication blockade, has been recently described as a pattern
recognition receptor able to initiate innate immune response
upon retroviral capsid lattice recognition, (Battivelli et al.,
2011; Pertel et al., 2011). Bone marrow stromal cell antigen-2
is a type I IFN-inducible restriction factor that can potently
block HIV-1 release in cell-to-cell transmission of HIV-1.
However, it may not be able to restrict DC-mediated HIV-1
capture and transfer (Coleman et al., 2011; Blanchet et al.,
2013).
However, the most likely potent restriction in DCs and
myeloid cells is the recently identified SAMHD1, blocking at
the post-entry step (Hrecka et al., 2011; Laguette et al., 2011).
This DC restriction factor was discovered from a study on SIV
viral accessory protein X. SAMHD1 functions as a deoxy-
nucleoside triphosphate triphosphohydrolase (Goldstone
et al., 2011; Lahouassa et al., 2012), which reduces the
intracellular dNTP pool, and causes inhibition of reverse
transcription and complementary DNA synthesis, thereby
depriving HIV-1 of the necessary building blocks. However,
this theory was challenged recently, as it was reported that
SAMHD1 restriction activity could be separable from its
triphosphohydrolase activity (White et al., 2013). Primary
myeloid DCs and pDCs express high levels of SAMHD1,
resulting in poor induction of SAMHD1 degradation and poor
enhancement of HIV-1 infection in these cells (Bloch et al.,
2013).
In acute HIV infection, the first detectable plasma cytokines
are type I IFNs, which are most likely produced by mucosal
and local immune cells (pDCs, DCs, LCs) sensing ssRNA
(Stacey et al., 2009).
It is well established that type I IFN is one of the many
cytokines that can induce the maturation of DCs (Santini et al.,
2000), and it is this maturation that has been shown to block
HIV-1 infection at a post-entry level (Dong et al., 2007).
In pDCs, type I IFN production is induced by HIV-1
infection, resulting in the inhibition of HIV-1 replication
(Meylan et al., 1993; Groot et al., 2006) independent of
SAMHD1 (Goujon et al., 2013). Recently, another molecule,
(SLFN 11), induced by type I IFN was recently shown to
inhibit the translation of HIV-1 (Li et al., 2012). In addition, a
role for IFN-a in restriction was recently demonstrated by
showing that HIV-1 uses cleavage and polyadenylation
specificity factor subunit 6 and cyclophilins (Nup358 and
CypA) to cloak its replication in primary human macrophages
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(Manel et al., 2010; Schaller et al., 2011; Rasaiyaah et al.,
2013), allowing it to evade innate immune sensors and the
induction of innate immune responses.
The IFN-induced myxovirus resistance 2 protein has also
been shown to be a key effector of IFN-a-mediated resistance
to multiple HIV strains by blocking at a late post-entry stage
(Goujon et al., 2013; Kane et al., 2013). Although multiple
blocks to infection exist, HIV-1 has been shown to exploit
innate immune signaling pathways to facilitate productive
infection of DCs. DCs express pattern recognition receptors
including Toll-like receptors and CLRs. Toll-like receptor
signaling pathways are induced by HIV-1 in DCs to promote
replication and cell-to-cell transmission (Gringhuis et al.,
2010). Despite HIV-1 replication being very limited in DCs,
intracellular recognition of virus and subsequent immune
activation appears to be subdued by host factors (Iwasaki,
2012). Deletion of the three prime repair exonuclease leads to
accumulation of defective HIV-1 viral DNA products and
production of type I IFN (Stetson et al., 2008). This has been
shown to be via activation of an unknown cytoplasmic sensor,
mediated by stimulator of IFN genes, TANK-binding kinase 1,
and IFN regulatory factor 3 (Yan et al., 2010). The recently
identified enzyme cGAMP synthase has been shown as a
cytosolic DNA sensor that triggers the production of type I
IFNs and other cytokines (Lahaye et al., 2013; Sun et al.,
2013). It functions as a second messenger binding to and
activating the endoplasmic reticulum protein stimulator of IFN
genes (Ablasser et al., 2013; Zhang et al., 2013; Gao et al.,
2013b). Stimulator of IFN genes subsequently activates TANK-
binding kinase 1, which then activates transcription factors
NF-kB and IFN regulatory factor 3 to induce IFNs and other
cytokines (Barber, 2011).
HIV-1 can induce the production of cGAMP via cGAMP
synthase under permissive conditions, suggesting that cGAMP
may also be employed to bypass the block of innate immune
responses against HIV (Gao et al., 2013a).
Together, these recent findings indicate that there are yet
undiscovered additional restriction factors relating to type I
IFN signaling in DCs and that these have the potential to be
exploited to fight retroviral infections.
EFFECT OF COINFECTIONS ON LCs AND HIV-1
SUSCEPTIBILITY
The risk of HIV-1 infection increases in the presence of
coinfection from sexually transmitted diseases by increasing
inflammation and influx of activated CD4þ T cells (de Jong
et al., 2008). Any protective function of Langerin against HIV-1
is also removed by sexually transmitted disease coinfections
such as herpes simplex virus (HSV) or Candida species (de
Jong et al., 2010a). Both HSV-2 and Candida species occupy
the Langerin receptor, obstructing Langerin function and
subsequently increasing the risk of HIV-1 infection (Turville
et al., 2003; de Jong et al., 2010b). HSV-2 is also able to infect
LCs, decreasing Langerin expression and its protective role.
HSV-2 enhances the HIV susceptibility of LCs within skin
explants. Epidermal LCs exposed to HSV-2 and HIV-1 were
rarely co-infected with these viruses. Instead, keratinocytes
infected with HSV-2 increased their production of the anti-
microbial peptide LL-37, which enhanced HIV susceptibility
in monocyte-derived LC through upregulating their expression
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of HIV-1 co-receptors, but not affecting restriction factors such
as Langerin, APOBEC3G, or SAMHD1 (Ogawa et al., 2013).
Sexually transmitted pathogens such as Candida albicans and
Neisseria gonorrhea and pathogenic bacteria from bacterial
vaginosis such as Listeria monocytogenes and Staphylococcus
aureus have been shown to improve HIV-1 capture and/or
infection in LCs, which led to increased transmission to T cells
via Toll-like receptors2 triggering, and subsequently reduced
expression of Langerin and APOBEC3G (Ogawa et al., 2009;
de Jong et al., 2010a). Moreover, C.albicans, N.gonorrhea,
and HSV-2 enhance HIV-1 production in LCs and transfer to T
cells via tumor necrosis factor-a local production (de Jong
et al., 2008, 2010a). Therefore, it appears that during coin-
fections, concomitant sexually transmitted diseases infection
alters HIV-1 susceptibility and the functional ability of Langerin
in LCs directly and indirectly, thereby potentially increasing
the risk of acquiring HIV-1 infection and transmission of HIV-1
to T cells.
CONCLUSION AND FUTURE DIRECTIONS
Of the vaccines tested in clinical efficacy trials in humans over
the last 30 years, the RV144 phase 3 study conducted in a
low-risk population in Thailand showed a 31% reduction in
the rate of HIV-1 acquisition. (Rerks-Ngarm et al., 2009).
Antibodies elicited by the vaccine against the HIV-1 envelope
correlated with a reduced risk of infection (Haynes et al.,
2012; Pollara et al., 2014). DCs are likely to be important
targets for any vaccine candidate, because of their critical role
in the initiation and shaping of adaptive immune responses.
Despite the above mentioned advances in vaccine develop-
ment and in the interim absence of an effective vaccine,
chemoprophylaxis in the form of topical microbicides may be
an alternative. In a double-blind, randomized controlled trial
on the effectiveness of a 1% vaginal gel formulation, Tenofovir
(reverse transcriptase inhibitor) showed up to 39% reduction
in HIV-1 incidence in women (Abdool Karim et al., 2010;
Cottrell and Kashuba, 2014).
In another study, it was demonstrated that oral CCR5
inhibitor, Maraviroc, can block HIV-1 infection of epidermal
LCs in an ex vivo model and a newly discovered reverse
transcriptase inhibitor, EFdA, can be a potent microbicide to
prevent HIV-1 infection instead of condom use (Matsuzawa
et al., 2013, 2014)
A further development is an experimental injectable pre-
exposure prophylaxis drug GSK 744 (HIV-1 integrase inhibi-
tor) shown in macaques to give long lasting protection against
a hybrid simian-human AIDS virus (Andrews et al., 2014).
In addition, stimulation of autophagy in DCs leads to
more rapid and robust adaptive immune responses against
HIV-1 (Blanchet et al., 2010), therefore targeting stimulation of
autophagy in the early events of HIV-1 infection in mucosal
tissues could represent a method to circumvent viral pro-
pagation (Shoji-Kawata et al., 2013).
In summary, future studies will need to delineate which
human DC subset(s) is central to antigen uptake and induction
of immunity, in order to enhance microbicides and vaccine
efficacy in preventing HIV-1 transmission across mucosal
surfaces.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This study was supported by Wellcome Trust Institutional Strategic Support
Fund to Cardiff University (506398) and Gates Foundation Grant to VP; ZA is a
recipient of WCAT fellowship (http://www.walesdeanery.org/index.php/
wcat.html). The funders had no role in the study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
REFERENCES
Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. (2010) Effectiveness and
safety of tenofovir gel, an antiretroviral microbicide, for the prevention of
HIV infection in women. Science 329:1168–74
Ablasser A, Goldeck M, Cavlar T et al. (2013) cGAS produces a 2’-5’-linked
cyclic dinucleotide second messenger that activates STING. Nature
498:380–4
Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate
immunity. Cell 124:783–801
Altfeld M, Fadda L, Frleta D et al. (2011) DCs and NK cells: critical effectors in
the immune response to HIV-1. Nat Rev Immunol 11:176–86
Andrews CD, Spreen WR, Mohri H et al. (2014) Long-acting integrase inhibitor
protects macaques from intrarectal simian/human immunodeficiency
virus. Science 343:1151–4
Arrighi JF, Pion M, Garcia E et al. (2004) DC-SIGN-mediated infectious
synapse formation enhances X4 HIV-1 transmission from dendritic cells
to T cells. J Exp Med 200:1279–88
Ballweber L, Robinson B, Kreger A et al. (2011) Vaginal langerhans cells
nonproductively transporting HIV-1 mediate infection of T cells. J Virol
85:13443–7
Banchereau J, Steinman RM (1998) Dendritic cells and the control of
immunity. Nature 392:245–52
Barber GN (2011) Cytoplasmic DNA innate immune pathways. Immunol Rev
243:99–108
Battivelli E, Migraine J, Lecossier D et al. (2011) Modulation of TRIM5alpha
activity in human cells by alternatively spliced TRIM5 isoforms. J Virol
85:7828–35
Berger G, Durand S, Fargier G et al. (2011) APOBEC3A is a specific inhibitor of
the early phases of HIV-1 infection in myeloid cells. PLoS Pathog
7:e1002221
Blanchet FP, Moris A, Nikolic DS et al. (2010) Human immunodeficiency
virus-1 inhibition of immunoamphisomes in dendritic cells impairs early
innate and adaptive immune responses. Immunity 32:654–69
Blanchet FP, Stalder R, Czubala M et al. (2013) TLR-4 engagement of
dendritic cells confers a BST- 2/tetherin-mediated restriction of HIV-1
infection to CD4þ T cells across the virological synapse. Retrovirology
10:6
Bloch N, O’Brien M, Norton TD et al. (2013) HIV Type 1 infection of
plasmacytoid and myeloid dendritic cells is restricted by high levels of
SAMHD1 and cannot be counteracted by Vpx. AIDS Res Hum Retro-
viruses 30:195–203
Brenchley JM, Schacker TW, Ruff LE et al. (2004) CD4þ T cell depletion
during all stages of HIV disease occurs predominantly in the gastro-
intestinal tract. J Exp Med 200:749–59
Cavrois M, Neidleman J, Kreisberg JF et al. (2007) In vitro derived dendritic
cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions.
PLoS Pathog 3:e4
Choudhuri K, Llodra J, Roth EW et al. (2014) Polarized release of T-cell-
receptor-enriched microvesicles at the immunological synapse. Nature
507:118–23
Chu CC, Ali N, Karagiannis P et al. (2012) Resident CD141 (BDCA3)þ
dendritic cells in human skin produce IL-10 and induce regulatory T cells
that suppress skin inflammation. J Exp Med 209:935–45
Coleman CM, Spearman P, Wu L (2011) Tetherin does not significantly restrict
dendritic cell- mediated HIV-1 transmission and its expression is upregu-
lated by newly synthesized HIV-1 Nef. Retrovirology 8:26
Z Ahmed et al.
Role of DCs in HIV-1 Infection
1230 Journal of Investigative Dermatology (2015), Volume 135
Cottrell ML, Kashuba AD (2014) Topical microbicides and HIV prevention in
the female genital tract. J Clin Pharmacol 54:603–15
Cunningham AL, Carbone F, Geijtenbeek TB (2008) Langerhans cells and viral
immunity. Eur J Immunol 38:2377–85
de Jong MA, de Witte L, Oudhoff MJ et al. (2008) TNF-alpha and TLR agonists
increase susceptibility to HIV-1 transmission by human Langerhans cells
ex vivo. J Clin Invest 118:3440–52
de Jong MA, de Witte L, Taylor ME et al. (2010a) Herpes simplex virus type 2
enhances HIV-1 susceptibility by affecting Langerhans cell function.
J Immunol 185:1633–41
de Jong MA, Vriend LE, Theelen B et al. (2010b) C-type lectin Langerin is a
beta-glucan receptor on human Langerhans cells that recognizes oppor-
tunistic and pathogenic fungi. Mol Immunol 47:1216–25
de Witte L, Bobardt M, Chatterji U et al. (2007a) Syndecan-3 is a dendritic cell-
specific attachment receptor for HIV-1. Proc Natl Acad Sci USA
104:19464–9
de Witte L, Nabatov A, Pion M et al. (2007b) Langerin is a natural barrier to
HIV-1 transmission by Langerhans cells. Nat Med 13:367–71
Dong C, Janas AM, Wang JH et al. (2007) Characterization of human
immunodeficiency virus type 1 replication in immature and mature
dendritic cells reveals dissociable cis- and trans-infection. J Virol
81:11352–62
Engering A, Geijtenbeek TB, van Vliet SJ et al. (2002) The dendritic cell-
specific adhesion receptor DC-SIGN internalizes antigen for presentation
to T cells. J Immunol 168:2118–26
Fahrbach KM, Barry SM, Ayehunie S et al. (2007) Activated CD34-derived
Langerhans cells mediate transinfection with human immunodeficiency
virus. J Virol 81:6858–68
Felts RL, Narayan K, Estes JD et al. (2010) 3D visualization of HIV transfer at
the virological synapse between dendritic cells and T cells. Proc Natl
Acad Sci USA 107:13336–41
Ganor Y, Drillet-Dangeard AS, Lopalco L et al. (2013) Calcitonin gene-related
peptide inhibits Langerhans cell-mediated HIV-1 transmission. J Exp Med
210:2161–70
Ganor Y, Zhou Z, Tudor D et al. (2010) Within 1h, HIV-1 uses viral synapses to
enter efficiently the inner, but not outer, foreskin mucosa and engages
Langerhans-T cell conjugates. Mucosal Immunol 3:506–22
Gao D, Wu J, Wu YT et al. (2013a) Cyclic GMP-AMP synthase is an innate
immune sensor of HIV and other retroviruses. Science 341:903–6
Gao P, Ascano M, Wu Y et al. (2013b) Cyclic [G(2’,5’)pA(3’,5’)p] is the
metazoan second messenger produced by DNA-activated cyclic GMP-
AMP synthase. Cell 153:1094–107
Garcia E, Nikolic DS, Piguet V (2008) HIV-1 replication in dendritic cells
occurs through a tetraspanin- containing compartment enriched in AP-3.
Traffic 9:200–14
Garcia E, Pion M, Pelchen-Matthews A et al. (2005) HIV-1 trafficking to the
dendritic cell-T-cell infectious synapse uses a pathway of tetraspanin
sorting to the immunological synapse. Traffic 6:488–501
Geijtenbeek TB, Kwon DS, Torensma R et al. (2000) DC-SIGN, a dendritic
cell-specific HIV-1-binding protein that enhances trans-infection of T
cells. Cell 100:587–97
Goldstone DC, Ennis-Adeniran V, Hedden JJ et al. (2011) HIV-1 restriction
factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase.
Nature 480:379–82
Goujon C, Moncorge O, Bauby H et al. (2013) Human MX2 is an interferon-
induced post-entry inhibitor of HIV-1 infection. Nature 502:559–62
Granelli-Piperno A, Shimeliovich I, Pack M et al. (2006) HIV-1 selectively
infects a subset of nonmaturing BDCA1-positive dendritic cells in human
blood. J Immunol 176:991–8
Gringhuis SI, van der Vlist M, van den Berg LM et al. (2010) HIV-1 exploits
innate signaling by TLR8 and DC-SIGN for productive infection of
dendritic cells. Nat Immunol 11:419–26
Groot F, van Capel TM, Kapsenberg ML et al. (2006) Opposing roles of
blood myeloid and plasmacytoid dendritic cells in HIV-1 infection of T
cells: transmission facilitation versus replication inhibition. Blood
108:1957–64
Gummuluru S, Rogel M, Stamatatos L et al. (2003) Binding of human
immunodeficiency virus type 1 to immature dendritic cells can occur
independently of DC-SIGN and mannose binding C-type lectin receptors
via a cholesterol-dependent pathway. J Virol 77:12865–74
Haase AT (2010) Targeting early infection to prevent HIV-1 mucosal transmis-
sion. Nature 464:217–23
Haniffa M, Shin A, Bigley V et al. (2012) Human tissues contain CD141hi
cross-presenting dendritic cells with functional homology to mouse
CD103þ nonlymphoid dendritic cells. Immunity 37:60–73
Harman AN, Bye CR, Nasr N et al. (2013a) Identification of lineage relation-
ships and novel markers of blood and skin human dendritic cells.
J Immunol 190:66–79
Harman AN, Kim M, Nasr N et al. (2013b) Tissue dendritic cells as portals for
HIV entry. Rev Med Virol 23:319–33
Harris A, Borgnia MJ, Shi D et al. (2011) Trimeric HIV-1 glycoprotein gp140
immunogens and native HIV-1 envelope glycoproteins display the same
closed and open quaternary molecular architectures. Proc Natl Acad Sci
USA 108:11440–5
Hatch SC, Archer J, Gummuluru S (2009) Glycosphingolipid composition of
human immunodeficiency virus type 1 (HIV-1) particles is a crucial
determinant for dendritic cell-mediated HIV-1 trans- infection. J Virol
83:3496–506
Haynes BF, Gilbert PB, McElrath MJ et al. (2012) Immune-correlates analysis of
an HIV-1 vaccine efficacy trial. N Engl J Med 366:1275–86
Hladik F, Sakchalathorn P, Ballweber L et al. (2007) Initial events in
establishing vaginal entry and infection by human immunodeficiency
virus type-1. Immunity 26:257–70
Hrecka K, Hao C, Gierszewska M et al. (2011) Vpx relieves inhibition of HIV-1
infection of macrophages mediated by the SAMHD1 protein. Nature
474:658–61
Hu J, Gardner MB, Miller CJ (2000) Simian immunodeficiency virus rapidly
penetrates the cervicovaginal mucosa after intravaginal inoculation and
infects intraepithelial dendritic cells. J Virol 74:6087–95
Iwasaki A (2012) Innate immune recognition of HIV-1. Immunity 37:389–98
Izquierdo-Useros N, Blanco J, Erkizia I et al. (2007) Maturation of blood-
derived dendritic cells enhances human immunodeficiency virus type 1
capture and transmission. J Virol 81:7559–70
Izquierdo-Useros N, Naranjo-Gomez M, Archer J et al. (2009) Capture and
transfer of HIV-1 particles by mature dendritic cells converges with the
exosome-dissemination pathway. Blood 113:2732–41
Kane M, Yadav SS, Bitzegeio J et al. (2013) MX2 is an interferon-induced
inhibitor of HIV-1 infection. Nature 502:563–6
Kawamura T, Cohen SS, Borris DL et al. (2000) Candidate microbicides block
HIV-1 infection of human immature Langerhans cells within epithelial
tissue explants. J Exp Med 192:1491–500
Kawamura T, Gulden FO, Sugaya M et al. (2003) R5 HIV productively infects
Langerhans cells, and infection levels are regulated by compound CCR5
polymorphisms. Proc Natl Acad Sci USA 100:8401–6
Kawamura T, Qualbani M, Thomas EK et al. (2001) Low levels of productive
HIV infection in Langerhans cell-like dendritic cells differentiated in the
presence of TGF-beta1 and increased viral replication with CD40 ligand-
induced maturation. Eur J Immunol 31:360–8
Kirchhoff F (2010) Immune evasion and counteraction of restriction factors by
HIV-1 and other primate lentiviruses. Cell Host Microbe 8:55–67
Laguette N, Benkirane M (2012) How SAMHD1 changes our view of viral
restriction. Trends Immunol 33:26–33
Laguette N, Sobhian B, Casartelli N et al. (2011) SAMHD1 is the dendritic- and
myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature
474:654–7
Lahaye X, Satoh T, Gentili M et al. (2013) The capsids of HIV-1 and HIV-2
determine immune detection of the viral cDNA by the innate sensor cGAS
in dendritic cells. Immunity 39:1132–42
Lahouassa H, Daddacha W, Hofmann H et al. (2012) SAMHD1 restricts the
replication of human immunodeficiency virus type 1 by depleting the
intracellular pool of deoxynucleoside triphosphates. Nat Immunol
13:223–8
Z Ahmed et al.
Role of DCs in HIV-1 Infection
www.jidonline.org 1231
Lambert AA, Barabe F, Gilbert C et al. (2011) DCIR-mediated enhancement of
HIV-1 infection requires the ITIM-associated signal transduction pathway.
Blood 117:6589–99
Lambert AA, Gilbert C, Richard M et al. (2008) The C-type lectin surface
receptor DCIR acts as a new attachment factor for HIV-1 in dendritic cells
and contributes to trans- and cis-infection pathways. Blood 112:1299–307
Lederman MM, Veazey RS, Offord R et al. (2004) Prevention of vaginal SHIV
transmission in rhesus macaques through inhibition of CCR5. Science
306:485–7
Lenz A, Heine M, Schuler G et al. (1993) Human and murine dermis contain
dendritic cells. Isolation by means of a novel method and phenotypical
and functional characterization. J Clin Invest 92:2587–96
Li M, Kao E, Gao X et al. (2012) Codon-usage-based inhibition of HIV protein
synthesis by human schlafen 11. Nature 491:125–8
Li Q, Duan L, Estes JD et al. (2005) Peak SIV replication in resting memory
CD4þ T cells depletes gut lamina propria CD4þ T cells. Nature
434:1148–52
Liu YJ (2001) Dendritic cell subsets and lineages, and their functions in innate
and adaptive immunity. Cell 106:259–62
Manches O, Fernandez MV, Plumas J et al. (2012) Activation of the
noncanonical NF-kappaB pathway by HIV controls a dendritic cell
immunoregulatory phenotype. Proc Natl Acad Sci USA 109:14122–7
Manches O, Frleta D, Bhardwaj N (2014) Dendritic cells in progression and
pathology of HIV infection. Trends Immunol 35:114–22
Manel N, Hogstad B, Wang Y et al. (2010) A cryptic sensor for HIV-1 activates
antiviral innate immunity in dendritic cells. Nature 467:214–7
Matsuzawa T, Kawamura T, Ogawa Y et al. (2014) EFdA, a reverse
transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of
Langerhans cells within epithelium. J Invest Dermatol 134:1158–61
Matsuzawa T, Kawamura T, Ogawa Y et al. (2013) Oral administration of the
CCR5 inhibitor, maraviroc, blocks HIV ex vivo infection of Langerhans
cells within the epithelium. J Invest Dermatol 133:2803–5
Mattapallil JJ, Douek DC, Hill B et al. (2005) Massive infection and loss of
memory CD4þ T cells in multiple tissues during acute SIV infection.
Nature 434:1093–7
McDonald D, Wu L, Bohks SM et al. (2003) Recruitment of HIV and its
receptors to dendritic cell-T cell junctions. Science 300:1295–7
Mehandru S, Poles MA, Tenner-Racz K et al. (2004) Primary HIV-1 infection is
associated with preferential depletion of CD4þ T lymphocytes from
effector sites in the gastrointestinal tract. J Exp Med 200:761–70
Meylan PR, Guatelli JC, Munis JR et al. (1993) Mechanisms for the inhibition of
HIV replication by interferons-alpha, -beta, and -gamma in primary
human macrophages. Virology 193:138–48
Mohanram V, Skold AE, Bachle SM et al. (2013) IFN-alpha induces APO-
BEC3G, F, and A in immature dendritic cells and limits HIV-1 spread to
CD4þ T cells. J Immunol 190:3346–53
Moris A, Pajot A, Blanchet F et al. (2006) Dendritic cells and HIV-specific
CD4þ T cells: HIV antigen presentation, T-cell activation, and viral
transfer. Blood 108:1643–51
Murooka TT, Deruaz M, Marangoni F et al. (2012) HIV-infected T cells are
migratory vehicles for viral dissemination. Nature 490:283–7
Nestle FO, Zheng XG, Thompson CB et al. (1993) Characterization of dermal
dendritic cells obtained from normal human skin reveals phenotypic and
functionally distinctive subsets. J Immunol 151:6535–45
Nikolic DS, Lehmann M, Felts R et al. (2011) HIV-1 activates Cdc42 and
induces membrane extensions in immature dendritic cells to facilitate
cell-to-cell virus propagation. Blood 118:4841–52
Nobile C, Petit C, Moris A et al. (2005) Covert human immunodeficiency virus
replication in dendritic cells and in DC-SIGN-expressing cells promotes
long-term transmission to lymphocytes. J Virol 79:5386–99
O’Brien M, Manches O, Sabado RL et al. (2011) Spatiotemporal trafficking of HIV
in human plasmacytoid dendritic cells defines a persistently IFN-alpha-
producing and partially matured phenotype. J Clin Invest 121:1088–101
Ogawa Y, Kawamura T, Kimura T et al. (2009) Gram-positive bacteria enhance
HIV-1 susceptibility in Langerhans cells, but not in dendritic cells, via
Toll-like receptor activation. Blood 113:5157–66
Ogawa Y, Kawamura T, Matsuzawa T et al. (2013) Antimicrobial peptide
LL-37 produced by HSV-2- infected keratinocytes enhances HIV infection
of Langerhans cells. Cell Host Microbe 13:77–86
Pavli P, Hume DA, Van De Pol E et al. (1993) Dendritic cells, the major
antigen-presenting cells of the human colonic lamina propria. Immunol-
ogy 78:132–41
Pelchen-Matthews A, Kramer B, Marsh M (2003) Infectious HIV-1 assembles in
late endosomes in primary macrophages. J Cell Biol 162:443–55
Peressin M, Proust A, Schmidt S et al. (2014) Efficient transfer of HIV-1 in trans
and in cis from Langerhans dendritic cells and macrophages to autologous
T lymphocytes. AIDS 28:667–77
Pertel T, Hausmann S, Morger D et al. (2011) TRIM5 is an innate immune
sensor for the retrovirus capsid lattice. Nature 472:361–5
Piguet V, Steinman RM (2007) The interaction of HIV with dendritic cells:
outcomes and pathways. Trends Immunol 28:503–10
Pion M, Arrighi JF, Jiang J et al. (2007) Analysis of HIV-1-X4 fusion with
immature dendritic cells identifies a specific restriction that is indepen-
dent of CXCR4 levels. J Invest Dermatol 127:319–23
Pion M, Granelli-Piperno A, Mangeat B et al. (2006) APOBEC3G/3F mediates
intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection.
J Exp Med 203:2887–93
Pollara J, Bonsignori M, Moody MA et al. (2014) HIV-1 vaccine-induced C1
and V2 Env-specific antibodies synergize for increased antiviral activities.
J Virol 88:7715–26
Popov S, Chenine AL, Gruber A et al. (2005) Long-term productive human
immunodeficiency virus infection of CD1a-sorted myeloid dendritic cells.
J Virol 79:602–8
Puryear WB, Akiyama H, Geer SD et al. (2013) Interferon-inducible mechan-
ism of dendritic cell- mediated HIV-1 dissemination is dependent on
Siglec-1/CD169. PLoS Pathog 9:e1003291
Rasaiyaah J, Tan CP, Fletcher AJ et al. (2013) HIV-1 evades innate immune
recognition through specific cofactor recruitment. Nature 503:402–5
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. (2009) Vaccination with
ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J
Med 361:2209–20
Romani N, Brunner PM, Stingl G (2012) Changing views of the role of
Langerhans cells. J Invest Dermatol 132:872–81
Sandgren KJ, Smed-Sorensen A, Forsell MN et al. (2013) Human plasmacytoid
dendritic cells efficiently capture HIV-1 envelope glycoproteins via CD4
for antigen presentation. J Immunol 191:60–9
Santini SM, Lapenta C, Logozzi M et al. (2000) Type I interferon as a powerful
adjuvant for monocyte-derived dendritic cell development and activity
in vitro and in Hu-PBL-SCID mice. J Exp Med 191:1777–88
Schaller T, Ocwieja KE, Rasaiyaah J et al. (2011) HIV-1 capsid-cyclophilin
interactions determine nuclear import pathway, integration targeting and
replication efficiency. PLoS Pathog 7:e1002439
Schmidt B, Ashlock BM, Foster H et al. (2005) HIV-infected cells are major
inducers of plasmacytoid dendritic cell interferon production, maturation,
and migration. Virology 343:256–66
Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme
APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
Nat Med 9:1404–7
Shoji-Kawata S, Sumpter R, Leveno M et al. (2013) Identification of a candidate
therapeutic autophagy-inducing peptide. Nature 494:201–6
Smed-Sorensen A, Lore K, Vasudevan J et al. (2005) Differential susceptibility
to human immunodeficiency virus type 1 infection of myeloid and
plasmacytoid dendritic cells. J Virol 79:8861–9
Stacey AR, Norris PJ, Qin L et al. (2009) Induction of a striking
systemic cytokine cascade prior to peak viremia in acute human
immunodeficiency virus type 1 infection, in contrast to more modest
and delayed responses in acute hepatitis B and C virus infections. J Virol
83:3719–33
Steinman RM (2012) Decisions about dendritic cells: past, present, and future.
Annu Rev Immunol 30:1–22
Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine.
Nature 449:419–26
Z Ahmed et al.
Role of DCs in HIV-1 Infection
1232 Journal of Investigative Dermatology (2015), Volume 135
Steinman RM, Cohn ZA (1973) Identification of a novel cell type in peripheral
lymphoid organs of mice. I. Morphology, quantitation, tissue distribution.
J Exp Med 137:1142–62
Stetson DB, Ko JS, Heidmann T et al. (2008) Trex1 prevents cell-intrinsic
initiation of autoimmunity. Cell 134:587–98
Sun L, Wu J, Du F et al. (2013) Cyclic GMP-AMP synthase is a cytosolic DNA
sensor that activates the type I interferon pathway. Science 339:786–91
Trumpfheller C, Park CG, Finke J et al. (2003) Cell type-dependent retention
and transmission of HIV-1 by DC-SIGN. Int Immunol 15:289–98
Turville S, Wilkinson J, Cameron P et al. (2003) The role of dendritic cell
C-type lectin receptors in HIV pathogenesis. J Leukoc Biol 74:710–8
Turville SG, Cameron PU, Handley A et al. (2002) Diversity of receptors
binding HIV on dendritic cell subsets. Nat Immunol 3:975–83
Turville SG, Santos JJ, Frank I et al. (2004) Immunodeficiency virus uptake, turn-
over, and 2-phase transfer in human dendritic cells. Blood 103:2170–9
Valladeau J, Duvert-Frances V, Pin JJ et al. (1999) The monoclonal antibody
DCGM4 recognizes Langerin, a protein specific of Langerhans cells, and
is rapidly internalized from the cell surface. Eur J Immunol 29:2695–704
Valladeau J, Ravel O, Dezutter-Dambuyant C et al. (2000) Langerin, a novel
C-type lectin specific to Langerhans cells, is an endocytic receptor that
induces the formation of Birbeck granules. Immunity 12:71–81
van den Berg LM, Geijtenbeek TB (2013) Antiviral immune responses by
human langerhans cells and dendritic cells in HIV-1 infection. Adv Exp
Med Biol 762:45–70
Veazey RS, Klasse PJ, Schader SM et al. (2005) Protection of macaques from
vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell
fusion. Nature 438:99–102
White TE, Brandariz-Nunez A, Valle-Casuso JC et al. (2013) The retroviral
restriction ability of SAMHD1, but not its deoxynucleotide triphosphohy-
drolase activity, is regulated by phosphorylation. Cell Host Microbe
13:441–51
Wu L, KewalRamani VN (2006) Dendritic-cell interactions with HIV: infection
and viral dissemination. Nat Rev Immunol 6:859–68
Yan N, Regalado-Magdos AD, Stiggelbout B et al. (2010) The cytosolic
exonuclease TREX1 inhibits the innate immune response to human
immunodeficiency virus type 1. Nat Immunol 11:1005–13
Zhang X, Shi H, Wu J et al. (2013) Cyclic GMP-AMP containing mixed
phosphodiester linkages is an endogenous high-affinity ligand for STING.
Mol Cell 51:226–35
Zhou Z, Barry de Longchamps N, Schmitt A et al. (2011) HIV-1 efficient entry
in inner foreskin is mediated by elevated CCL5/RANTES that recruits T
cells and fuels conjugate formation with Langerhans cells. PLoS Pathog
7:e1002100
Z Ahmed et al.
Role of DCs in HIV-1 Infection
www.jidonline.org 1233
